Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 83%
In fiscal 2025, AIM ImmunoTech Inc. reported revenue of $0M, down 48.2% year over year. Operating margin was -13254.5% and net margin -15861.4%, on a free-cash-flow margin of n/a with capital expenditure at n/a of revenue. Every figure is computed directly from AIM's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $0M | -13254.5% | -15861.4% |
| FY2024 | $0M | -11630.6% | -10188.2% |
| FY2023 | $0M | -15800.0% | -14337.6% |
| FY2022 | $0M | -14129.8% | -13790.8% |
| FY2021 | $0M | -13954.1% | -14168.1% |
How does AIM compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.